Aviptadil as a promising intervention: a case study for TRALI treatment in a cardiac patient

Aviptadil is a synthetic Vasoactive Intestinal Polypeptide (VIP) discovered in 1970 by Said and Mutt(1). VIP binds to the VPAC1 receptor of the Alveolar Type (AT) II cell and has been shown to block replication of the Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) resulting in clinical and radiographic improvement. Sars-COV2 virus binds to the AT II cells via the Angiotensin-converting enzymes (ACE) 2 receptor. Unlike other anti-cytokine drugs, Aviptadil has a specific role in preserving lung surfactant production and protecting AT II cells.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Letter to Editor Source Type: research